Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cathay BiotechSHSE:688065 -0.13%92 EV-to-EBIT is 30.98 as of Sep. 16, 2026, which is 42% below its 10-year median of 53.23. GuruFocus rates SHSE:688065 with a GF Score™ of 92/100 and a GF Value™ of ¥49.85 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,290 Chemicals companies, Cathay Biotech ranks worse than 72.4% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Cathay Biotech's Enterprise Value for the quarter that ended in Jun. 2026 was ¥29,650 Mil.
Cathay Biotech's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥719 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cathay Biotech EV-to-EBIT Related Terms
Cathay Biotech EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Cathay Biotech's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Chemicals subindustry, Cathay Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cathay Biotech EV-to-EBIT vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Cathay Biotech's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Cathay Biotech's EV-to-EBIT falls into.
Cathay Biotech's current Enterprise Value is ¥22,270 Mil.
Cathay Biotech's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥719 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cathay Biotech (SHSE:688065) has a EV-to-EBIT of 30.98 as of Sep. 16, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Cathay Biotech and its competitors. This is 42% below median its historical median of 53.23. Over the past decade, Cathay Biotech's EV-to-EBIT has ranged from 30.21 to 101.08. According to the industry distribution chart, Cathay Biotech ranks #934 out of 1290 companies in the Chemicals industry, placing it in the top 72.4%.
Is Cathay Biotech's EV-to-EBIT too high?
Cathay Biotech's current EV-to-EBIT of 30.98 is 42% below median its 10-year median of 53.23. Over the past 10 years, this metric has ranged from a low of 30.21 to a high of 101.08. The Chemicals industry median EV-to-EBIT is 16.33. Cathay Biotech's value of 30.98 is 89.7% above this industry median. Based on the distribution chart, Cathay Biotech ranks #934 out of 1290 companies in the Chemicals industry, which is below the industry midpoint. Overall, Cathay Biotech has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cathay Biotech's EV-to-EBIT compare to DOW?
According to the Chemicals industry distribution chart, Cathay Biotech ranks #934 out of 1290 companies for EV-to-EBIT. This places Cathay Biotech in the lower half of its industry. The industry median EV-to-EBIT is 16.33. Cathay Biotech's value of 30.98 is 89.7% above this benchmark. Historically, Cathay Biotech's own EV-to-EBIT has ranged from 30.21 to 101.08 over the past decade. While the company's 10-year median is 53.23 vs. the industry median of 16.33, Cathay Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Chemicals company?
The median EV-to-EBIT among Chemicals companies is 16.33, based on 1,290 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cathay Biotech's current EV-to-EBIT of 30.98 is 89.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Cathay Biotech and its competitors. For the Chemicals industry, the median EV-to-EBIT is 16.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cathay Biotech's current EV-to-EBIT is 30.98, which is 42% below median its own 10-year median of 53.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cathay Biotech stock overvalued right now?
Based on GuruFocus' analysis, Cathay Biotech (SHSE:688065) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥49.85, compared to a current price of ¥37.48 — trading 24.8% below its estimated fair value. The current EV-to-EBIT is 30.98, which is 42% below median its 10-year median of 53.23 and 89.7% above the Chemicals industry median of 16.33. Cathay Biotech's overall GF Score™ is 92/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Cathay Biotech (SHSE:688065), the current EV-to-EBIT is 30.98 as of Sep. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cathay Biotech (SHSE:688065) Overvalued in 2026?
Based on GuruFocus' analysis, Cathay Biotech stock appears to be undervalued.
The current stock price of ¥37.48 is trading 24.8% below its estimated GF Value™ of ¥49.85.
GuruFocus considers Cathay Biotech to be Modestly Undervalued.
Key valuation signals for SHSE:688065:
EV-to-EBIT: 30.98 (42% below median its 10-year median of 53.23)
GF Value™: ¥49.85 vs. price of ¥37.48 (24.8% below fair value)
Industry Position: 89.7% above the Chemicals median (#934 of 1290)
No single metric tells the full story. See the SHSE:688065 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cathay Biotech Inc is engaged in research, development, production, and sales of new bio-based materials. The company owns the TERRYL brand, which focuses on bio-based polyamide fibers for textiles, and ECOPENT, which serves the engineering materials market.
92GF Score
Get the complete analysis for SHSE:688065
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688065 has been successfully added to your 
